209 related articles for article (PubMed ID: 34134766)
1. SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma.
Wu J; Zhang M; Faruq O; Zacksenhaus E; Chen W; Liu A; Chang H
Biomark Res; 2021 Jun; 9(1):48. PubMed ID: 34134766
[TBL] [Abstract][Full Text] [Related]
2. Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma.
Faruq O; Zhao D; Shrestha M; Vecchione A; Zacksenhaus E; Chang H
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326742
[TBL] [Abstract][Full Text] [Related]
3. MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma.
Zhang L; Rastgoo N; Wu J; Zhang M; Pourabdollah M; Zacksenhaus E; Chen Y; Chang H
Cancer Lett; 2020 Jun; 480():29-38. PubMed ID: 32220540
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma.
Rastgoo N; Wu J; Liu A; Pourabdollah M; Atenafu EG; Reece D; Chen W; Chang H
Haematologica; 2020 Dec; 105(12):2813-2823. PubMed ID: 33256380
[TBL] [Abstract][Full Text] [Related]
5. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
Yang J; Li X; Al-Lamki RS; Southwood M; Zhao J; Lever AM; Grimminger F; Schermuly RT; Morrell NW
Circ Res; 2010 Jul; 107(2):252-62. PubMed ID: 20522807
[TBL] [Abstract][Full Text] [Related]
6. GLIS3, a novel prognostic indicator of gastric adenocarcinoma, contributes to the malignant biological behaviors of tumor cells via modulating TGF-β1/TGFβR1/Smad1/5 signaling pathway.
Zhang Y; Wang B; Song H; Han M
Cytokine; 2023 Oct; 170():156342. PubMed ID: 37651918
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of ID protein by growth and differentiation factor 5 (GDF5) through a smad-dependent and MAPK-independent pathway in HUVSMC.
Chen X; Zankl A; Niroomand F; Liu Z; Katus HA; Jahn L; Tiefenbacher C
J Mol Cell Cardiol; 2006 Jul; 41(1):26-33. PubMed ID: 16716349
[TBL] [Abstract][Full Text] [Related]
8. TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK.
Bakkebø M; Huse K; Hilden VI; Smeland EB; Oksvold MP
BMC Immunol; 2010 Nov; 11():57. PubMed ID: 21092277
[TBL] [Abstract][Full Text] [Related]
9. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
10. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
11. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
12. Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway.
Wang Y; Dong F; Wan W; Zhang Z; Wang J; Wang H; Ke X
Hematology; 2020 Dec; 25(1):424-432. PubMed ID: 33191863
[TBL] [Abstract][Full Text] [Related]
13. SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma.
Zhou P; Xiao M; Li W; Sun X; Bai Y; Meng F; Zhu Z; Yuan W; Sun K
Front Pharmacol; 2022; 13():841308. PubMed ID: 35462913
[TBL] [Abstract][Full Text] [Related]
14. Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability.
Yao R; Zhang M; Zhou J; Liu L; Zhang Y; Gao J; Xu K
Cell Commun Signal; 2022 May; 20(1):73. PubMed ID: 35619182
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways.
Pannu J; Nakerakanti S; Smith E; ten Dijke P; Trojanowska M
J Biol Chem; 2007 Apr; 282(14):10405-13. PubMed ID: 17317656
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling.
Icli B; Wara AK; Moslehi J; Sun X; Plovie E; Cahill M; Marchini JF; Schissler A; Padera RF; Shi J; Cheng HW; Raghuram S; Arany Z; Liao R; Croce K; MacRae C; Feinberg MW
Circ Res; 2013 Nov; 113(11):1231-41. PubMed ID: 24047927
[TBL] [Abstract][Full Text] [Related]
17. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression of cav-1 in a subset of SSc fibroblasts contributes to constitutive Alk1/Smad1 activation.
Haines P; Hant FN; Lafyatis R; Trojanowska M; Bujor AM
J Cell Mol Med; 2012 Sep; 16(9):2238-46. PubMed ID: 22277251
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation.
Bariana M; Cassella E; Rateshwar J; Ouk S; Liou HC; Heller C; Colorado I; Feinman R; Makhdoom A; Siegel DS; Heller G; Tuckett A; Mondello P; Zakrzewski JL
Mol Cancer Ther; 2022 Dec; 21(12):1798-1809. PubMed ID: 36190955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
